Last reviewed · How we verify
Arelix (PIRETANIDE)
Piretanide (Arelix) is a marketed diuretic used primarily for the treatment of edema, competing in a class dominated by long-standing drugs such as furosemide, bumetanide, and torsemide. Its key strength lies in its mechanism of action, which effectively blocks the sodium-potassium-chloride cotransporter in the kidneys, potentially offering a more targeted approach to fluid management. The primary risk is the upcoming key composition patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | PIRETANIDE |
|---|---|
| Drug class | piretanide |
| Target | Solute carrier family 12 member 1 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Approved indications
- Edema
- Hypertensive disorder
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Arelix CI brief — competitive landscape report
- Arelix updates RSS · CI watch RSS